本报告期内，公司围绕主营业务稳健发展目标，整合现有优质技术资源，持续加大对新技术平台的战略 投入，稳步推进国内外产品注册认证工作，进一步巩固了行业内的长期竞争优势。同时，公司深入推进 以精益管理为核心的运营升级，持续提升运营效率与成本管控能力，提质增效成效显著。在国际化战略 方面，公司持续加大海外分支机构布局力度，海外市场拓展取得积极进展，相应销售费用有所增加，为 未来持续增长打开空间。 受外部环境及多重因素综合影响，本期净利润同比有所下降：主要系美国政府加征关税，导致部分区域 市场订单减少，公司承担部分关税成本使得营业成本上升；叠加汇率波动带来的汇兑损失、利息收入减 少及资产折旧摊销等因素共同影响所致。 （二）主要财务数据指标增减变动幅度达 30%以上的主要原因 证券之星消息，安旭生物近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润盈利 0.734亿元，同比减少61.84%。 业绩快报公告中对经营业绩和财务状况情况的说明： （一）报告期内公司的经营情况、财务状况及影响经营业绩的主要因素 报告期内，公司实现营业收入 45,357.51 万元，较上年同期下降 16.11%；实现归属于母公司所 ...

以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示： 资料显示，公司主营POCT试剂及仪器。 中证智能财讯安旭生物（688075）1月30日晚间披露2025年度业绩预告，预计2025年归母净利润7100万元至8500万元，同比下降55.8%-63.08%；扣非净利润 预计1300万元-1560万元，同比下降58.84%-65.7%。以1月30日收盘价计算，安旭生物目前市盈率（TTM）约为60.16倍-72.03倍，市净率（LF）约0.99倍，市 销率（TTM）约11.05倍。 此外，美国政府加征关税使得部分区域市场订单减少，公司承担部分关税导致营业成本上升，加上汇率波动引起汇兑损失、利息收入降低及资产折旧摊销等 多方面原因导致利润同比下滑。 指标注解： 据公告，公司业绩变动原因为， 报告期内，公司主营业务保持稳健发展，为巩固在产业领域内的长期竞争优势，公司保持原有几大技术平台的先进性之 外，持续加大对新技术平台的战略性投入，同时国内外市场及注册证书等拓展，海外分子公司的布局致使费用增加。 市盈率=总市值/净利润。当公司亏损时市盈率为负，此时用市盈率估值没有实际意义，往往用市净率或市销率做参考。 市 ...

截至9月30日，安旭生物股东户数6090.00，较上期增加1.10%；人均流通股20867股，较上期减少 1.08%。2025年1月-9月，安旭生物实现营业收入3.25亿元，同比减少19.34%；归母净利润6435.86万元， 同比减少52.60%。 1月22日，安旭生物跌0.46%，成交额3372.98万元。两融数据显示，当日安旭生物获融资买入额364.12 万元，融资偿还723.03万元，融资净买入-358.91万元。截至1月22日，安旭生物融资融券余额合计1.07 亿元。 融资方面，安旭生物当日融资买入364.12万元。当前融资余额1.07亿元，占流通市值的2.06%，融资余 额超过近一年70%分位水平，处于较高位。 融券方面，安旭生物1月22日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，杭州安旭生物科技股份有限公司位于浙江省杭州市莫干山路1418-50号4幢5层，成立日期 2008年7月4日，上市日期2021年11月18日，公司主营业务涉及POCT试剂及仪器的研发、生产与销售。 ...

Group 1 - The core viewpoint of the news is that Anxu Bio's financial performance has shown a decline in revenue and net profit, alongside low financing activity and high short-selling levels [1][2]. Group 2 - As of December 24, Anxu Bio's stock price increased by 0.03%, with a trading volume of 12.83 million yuan [1]. - On the same day, the financing buy amount was 1.45 million yuan, while the financing repayment was 2.52 million yuan, resulting in a net financing buy of -1.07 million yuan [1]. - The total financing and securities balance for Anxu Bio reached 94.92 million yuan, which is 1.93% of its market capitalization and below the 40th percentile level over the past year, indicating a low financing position [1]. - In terms of short selling, Anxu Bio had no shares sold or repaid on December 24, with a short selling balance of 0.00 yuan, indicating a high level compared to the 90th percentile over the past year [1]. Group 3 - For the period ending September 30, Anxu Bio reported a total revenue of 325 million yuan, a year-on-year decrease of 19.34%, and a net profit attributable to shareholders of 64.36 million yuan, down 52.60% year-on-year [2]. - The company has distributed a total of 895 million yuan in dividends since its A-share listing, with 657 million yuan distributed over the past three years [2]. - As of September 30, the number of shareholders increased to 6,090, while the average circulating shares per person decreased to 20,867 shares [2]. - Among the top ten circulating shareholders, Guangfa Value Core Mixed A ranked fifth with 3.5645 million shares, an increase of 549,800 shares from the previous period [2].

Group 1 - The core viewpoint of the news is that Anxu Bio's stock performance and financial metrics indicate a challenging period, with significant declines in revenue and net profit year-over-year [2] - On December 23, Anxu Bio's stock price remained unchanged at 0.00%, with a trading volume of 10.05 million yuan, and a net financing purchase of 241,600 yuan [1] - As of December 23, the total balance of margin trading for Anxu Bio was 95.99 million yuan, which is 1.95% of its market capitalization, indicating a low financing balance compared to the past year [1] Group 2 - For the period from January to September 2025, Anxu Bio reported a revenue of 325 million yuan, a year-over-year decrease of 19.34%, and a net profit of 64.36 million yuan, down 52.60% compared to the previous year [2] - The number of shareholders for Anxu Bio increased by 1.10% to 6,090 as of September 30, while the average number of circulating shares per person decreased by 1.08% to 20,867 shares [2] - Anxu Bio has distributed a total of 895 million yuan in dividends since its A-share listing, with 657 million yuan distributed over the past three years [2]

Group 1 - On November 11, Anxu Bio's stock rose by 4.39%, with a transaction volume of 99.73 million yuan [1] - The financing data for Anxu Bio on the same day showed a financing purchase amount of 7.39 million yuan and a financing repayment of 11.37 million yuan, resulting in a net financing outflow of 3.99 million yuan [1] - As of November 11, the total balance of margin trading for Anxu Bio was 94.49 million yuan, which is 1.75% of its circulating market value, indicating a low financing balance compared to the past year [1] Group 2 - As of September 30, Anxu Bio had 6,090 shareholders, an increase of 1.10% from the previous period, while the average circulating shares per person decreased by 1.08% to 20,867 shares [2] - For the period from January to September 2025, Anxu Bio reported operating revenue of 325 million yuan, a year-on-year decrease of 19.34%, and a net profit attributable to shareholders of 64.36 million yuan, down 52.60% year-on-year [2] - Since its A-share listing, Anxu Bio has distributed a total of 895 million yuan in dividends, with 657 million yuan distributed over the past three years [2]

Group 1 - Anxu Bio's stock increased by 5.03%, reaching 42.80 CNY per share, with a trading volume of 31.98 million CNY and a turnover rate of 0.61%, resulting in a total market capitalization of 5.439 billion CNY [1] - Anxu Bio, established on July 4, 2008, and listed on November 18, 2021, specializes in the research, production, and sales of POCT reagents and instruments, with 100% of its main business revenue coming from rapid diagnostic reagents [1] Group 2 - Among Anxu Bio's top ten circulating shareholders, GF Fund's Guangfa Value Core Mixed A (010377) increased its holdings by 549,800 shares in the third quarter, totaling 3.5645 million shares, which represents 2.8% of the circulating shares [2] - Guangfa Value Core Mixed A (010377) was established on January 22, 2021, with a current scale of 4.09 billion CNY, achieving a year-to-date return of 62.87% and ranking 441 out of 8147 in its category [2]

Core Viewpoint - Anxu Bio experienced a 2.22% increase in stock price on November 6, with a trading volume of 55.2043 million yuan, indicating positive market sentiment despite a decline in revenue and net profit year-on-year [1][2]. Financing Summary - On November 6, Anxu Bio had a financing buy-in of 5.655 million yuan, with a net financing buy of 191,300 yuan, reflecting active trading [1]. - The total financing and securities balance reached 99.7456 million yuan, accounting for 1.92% of the circulating market value, which is above the 50th percentile level over the past year, indicating a relatively high financing level [1]. - There were no short-selling activities on November 6, with a short-selling balance of 0.00 yuan, placing it in the 90th percentile level over the past year, suggesting a lack of bearish sentiment [1]. Financial Performance - For the period from January to September 2025, Anxu Bio reported a revenue of 325 million yuan, a year-on-year decrease of 19.34%, and a net profit attributable to shareholders of 64.3586 million yuan, down 52.60% year-on-year [2]. - Since its A-share listing, Anxu Bio has distributed a total of 895 million yuan in dividends, with 657 million yuan distributed over the past three years [2]. Shareholder Structure - As of September 30, 2025, Anxu Bio had 6,090 shareholders, an increase of 1.10% from the previous period, while the average circulating shares per person decreased by 1.08% to 20,867 shares [2]. - Among the top ten circulating shareholders, Guangfa Value Core Mixed A ranked fifth with 3.5645 million shares, an increase of 549,800 shares from the previous period [2].

Core Insights - Anxu Bio, established in July 2008 and listed on the Shanghai Stock Exchange in November 2021, is a leading company in the domestic POCT reagent field, with a full industry chain advantage and high product quality and technology level [1] Financial Performance - For Q3 2025, Anxu Bio reported revenue of 325 million yuan, ranking 21st out of 39 in the industry, significantly lower than the top competitor's revenue of 3.428 billion yuan and the second competitor's 3.127 billion yuan, as well as below the industry average of 708 million yuan and median of 330 million yuan [2] - The company's net profit for the same period was 64.31 million yuan, ranking 14th in the industry, again far below the top competitor's net profit of 1.588 billion yuan and the second competitor's 1.205 billion yuan, but higher than the industry median of 26.19 million yuan and lower than the industry average of 110 million yuan [2] Financial Ratios - Anxu Bio's debt-to-asset ratio for Q3 2025 was 8.59%, down from 11.21% in the previous year and below the industry average of 18.29%, indicating strong solvency [3] - The gross profit margin for the same period was 40.82%, a decrease from 42.11% year-on-year and lower than the industry average of 56.20%, suggesting a need for improvement in profitability [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 1.10% to 6,090, while the average number of circulating A-shares held per shareholder decreased by 1.08% to 20,900 [5] - Among the top ten circulating shareholders, Guangfa Value Core Mixed A ranked fifth with 3.5645 million shares, an increase of 549,800 shares from the previous period, while the eighth largest shareholder,招商景气优选股票A, held 600,000 shares, unchanged from the previous period [5]

Core Viewpoint - Anxu Bio experienced a slight increase in stock price and notable trading activity on September 25, 2023, with a focus on financing and stockholder data [1][2]. Group 1: Stock Performance and Trading Activity - On September 25, Anxu Bio's stock rose by 0.16%, with a trading volume of 17.95 million yuan [1]. - The financing buy-in amount for Anxu Bio on the same day was 4.54 million yuan, while the financing repayment was 2.36 million yuan, resulting in a net financing buy-in of 2.18 million yuan [1]. - As of September 25, the total financing and securities lending balance for Anxu Bio was 93.62 million yuan, which is 1.93% of its market capitalization and below the 50th percentile level over the past year, indicating a low financing balance [1]. Group 2: Securities Lending Activity - On September 25, Anxu Bio had no shares repaid or sold in securities lending, resulting in a sell amount of 0.00 yuan and a securities lending balance of 0.00 yuan, which is at a high level exceeding the 90th percentile over the past year [1]. Group 3: Financial Performance - For the first half of 2025, Anxu Bio reported a revenue of 230 million yuan, a year-on-year decrease of 7.42%, and a net profit attributable to shareholders of 59.31 million yuan, down 48.57% year-on-year [2]. - Since its A-share listing, Anxu Bio has distributed a total of 895 million yuan in dividends, with 657 million yuan distributed over the past three years [2]. Group 4: Shareholder Information - As of June 30, 2025, Anxu Bio had 6,024 shareholders, an increase of 1.50% from the previous period, with an average of 21,096 circulating shares per person, a decrease of 1.48% [2]. - Among the top ten circulating shareholders, Guangfa Value Core Mixed A held 3.01 million shares, unchanged from the previous period, while Zhaoshang Prosperity Preferred Stock A reduced its holdings by 10,000 shares to 600,000 shares [2].